The high price of some sophisticated medicines is often attributed as the root cause of some patients' deaths in third-world nations. Pharmaceutical companies are thus requested to sell their products at a discounted price in those parts of the world. I am convinced that only a reduction in prices from manufacturers is not going to solve the problem and in the following I will postulate my reasons. Disease-induced mortality rates have seen a significant downtrend over the last centuries in the developed countries whereas in the low per capita income regions this reduction is still staggering. This inspires the idea that treatment cost optimization can help the scenario and medicine is one of the top components in that budget. First of all, decreasing the selling price only from the company side will not stimulate the local governments to have a concrete sustainable healthcare plan for the long term. This will be just a temporary patch to deal with the scenario. Moreover, such action...